Summary
Other Scenarios:
- BAX - JNJ
- BAX - ABT
- JNJ - SRDX
- ABT - SRDX
| Buyer: | Baxter International Inc. (BAX) | Last Price: | 56.77 | Market Cap.: | 36.60B |
|---|---|---|---|---|---|
| Target: | SurModics, Inc. (SRDX) | Last Price: | 48.75 | Market Cap.: | 877.27M |
Lines of Business Summary:
- Baxter International Inc. (BAX) competes in 1 industry and 144 product/service groups
- SurModics, Inc. (SRDX) competes in 1 industry and 15 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Baxter International Inc. (BAX) has 1 and SurModics, Inc. (SRDX) has 0 suppliers that rely on a material % of their business. They share 0 in common.
- Baxter International Inc. (BAX) has 0 and SurModics, Inc. (SRDX) has 1 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
931 |
Biopharmaceuticals |
|
|
375 |
Healthcare Services |
|
154 | |
Medical Devices |
|
|
257 |
Nutritional Health |
|
29 | |
Outsourced Services |
|
|
67 |
Scientific Products |
|
37 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 208)
|
Target (Total: 21)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 15)
|
Target (Total: 1)
|
Buyer (Total: 14)
|
Target (Total: 22)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 48,000 | 146 |
| Revenue Per Employee | 236,397.7 | 474,954.6 |
| Total Revenue | 2,829.0 | 17.8 |
| Total Expenses | 2,305.0 | 10.2 |
Other Revenue
|
0.0 | 0.0 |
Cost of Revenue
|
1,437.0 | 1.2 |
SG&A Expense
|
621.0 | 2.8 |
Research & Development
|
177.0 | 6.2 |
Other Operating Expense
|
0.0 | 0.0 |
Operating Income
|
524.0 | 7.5 |
Unusual Income
|
70.0 | 0.0 |
LT Debt to Capital
|
23.47 | 0 |
Fwd P/E
|
20.83 | 37.37 |
Fwd P/Rev
|
3.28 | 12.15 |
| Book Value | 6,689.0 | 137.5 |
Curr Portion of LTD/Cap Lease
|
476.0 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused (
):
Healthcare > Medical Devices
Target
Focused (
):
Healthcare > Medical Devices > Medical Supplies > Surgical > Surgical Preparatory Accessories
Business Description
Buyer
Baxter International Inc. (Baxter) is a global diversified medical products and services company with capabilities in medical devices, pharmaceuticals and biotechnology that assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. Baxter?s products are used by hospitals, clinical and medical research laboratories, kidney dialysis centers, rehabilitation centers, nursing homes, doctors? offices and by patients at home under physician supervision. Baxter manufactures products in 28 countries and sells them in over 100 countries. The Company operates in three segments: The BioScience, Medication Delivery and Renal. In March 2007, Baxter completed the sale of its Transfusion Therapies business to Texas Pacific Group and Maverick Capital, Ltd.
Target
SurModics, Inc. (SurModics) is a provider of surface modification and drug delivery technologies to the healthcare industry. The Company is organized into three operating segments composed of six technology-centered and industry-focused business units: The Drug Delivery operating segment, the Hydrophilic and Other operating segment and the In Vitro operating segment. The Company's surface modification and drug delivery technologies are utilized by its medical device customers to either alter the characteristics of the surfaces of devices and biological materials, create new functions for the surfaces of the devices, or to enable drug delivery from its device platforms. On January 18, 2005, SurModics acquired all of the assets of InnoRx, Inc. In August 2007, SurModics acquired Brookwood Pharmaceuticals, Inc. from Southern Research Institute, and BioFX Laboratories, Inc., a provider of substrates to the in-vitro diagnostics industry.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
Gross Margin %
|
47.93 | 93.73 |
Operating Margin %
|
19.16 | 47.35 |
Quick Ratio
|
1.18 | 10.82 |
Current Ratio
|
1.89 | 11.32 |
Coverage Ratio
|
-0 | 0.15 |
| Total Assets | 14,659.0 | 164.9 |
| Return on Equity % | 24.52 | 17.12 |
| Return on Assets % | 11.19 | 14.28 |
Cash+ ST Inv. Per Share
|
3.76 | 2.58 |
| Total Debt | 2,717.0 | 0.0 |
| Total Debt to Equity % | 40.62 | 0 |
| Total Debt to Tangible Equity % | 58.92 | 0 |
Debt to Asset %
|
18.53 | 0.00 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
Healthcare Services |
|
|
Patient Care
The Patient Care Subsector is comprised of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
|
|
|
Medical Devices |
|
|
Anesthesiology
The Anesthesiology Subsector includes medical devices that deliver and monitor anesthetics.
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
Gastroenterology
The Gastroenterology Subsector includes medical devices that diagnosis and treat conditions affecting the stomach and intestinal tract.
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
Neurology
The Neurology Subsector includes medical devices that diagnose, monitor and treat neurological disorders.
|
|
|
Ophthalmology
The Ophthalmology Subsector includes medical devices that diagnose and treat eye disorders.
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
Respiratory
The Respiratory Subsector includes medical devices that diagnose and treat respiratory diseases.
|
|
|
Transfusion Medicine
The Transfusion Medicine Subsector includes medical devices and accessories that prepare or implement blood transfusion.
|
|
|
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
|
|
|
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
|
|
|
Nutritional Health |
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
Outsourced Services |
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
|
|
|
Scientific Products |
|
|
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Upper Respiratory |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
Cardiovascular System |
|
|
Heart Disorders |
|
|
Angina |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Arrhythmia |
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Buyer Products:
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
Myocardial Infarction (MI) |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Vascular Disorders |
|
|
Hypertension |
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Hypovolemia |
|
|
Plasma Volumizers |
|
|
Albumin-Based
Therapeutics based on plasma proteins that treat a decrease in circulating fluid (plasma) in the body by increasing plasma volume.
Buyer Products:
|
|
|
Thromboembolism |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Platelet Aggregation Inhibitors |
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Buyer Products:
|
|
|
Digestive System |
|
|
Gastrointestinal Tract Disorders |
|
|
Gastroesophageal Disorders |
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Buyer Products:
|
|
|
Nausea/Vomiting |
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
Endocrinology/Metabolism |
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Hematology |
|
|
Hemophilia |
|
|
Hemophilia A |
|
|
Clotting Agents
Therapeutics that aid in blood coagulation.
Buyer Products:
|
|
|
Hemophilia B |
|
|
Clotting Agents
Therapeutics that assist in blood coagulation.
Buyer Products:
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
Anemia |
|
|
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.
Buyer Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
Serum Factor Disorders |
|
|
Hypoalbuminemia |
|
|
Albumin-Based
Therapeutics based on plasma proteins that treat low levels of serum albumin.
Buyer Products:
|
|
|
Immunology |
|
|
Autoimmune Disorders |
|
|
Arthritis |
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
Idiopathic Thrombocytopenia Purpura (ITP) |
|
|
Immunoglobulins
Therapeutics that treat a decrease in platelets by neutralizing autoantibodies with therapeutic antibodies.
Buyer Products:
|
|
|
Kawasaki Syndrome |
|
|
Immunoglobulins
Therapeutics that treat Kawasaki Syndrome by neutralizing autoantibodies with therapeutic antibodies.
Buyer Products:
|
|
|
Immune Deficiency Disorders |
|
|
Primary Immunodeficiency Diseases |
|
|
Immunoglobulins
Therapeutics that treat primary immunodeficiency diseases by providing the body with therapeutic antibodies.
Buyer Products:
|
|
|
Infectious Diseases |
|
|
Bacterial |
|
|
Antibacterial Agents |
|
|
Broad Spectrum |
|
|
Antibiotics |
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
Narrow Spectrum |
|
|
Respiratory System |
|
|
Bronchitis |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
Pneumonia |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Buyer Products:
|
|
|
Tuberculosis |
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
Urology |
|
|
Urinary Tract Infections (UTI) |
|
|
Antibacterial Agents (Antibiotics) |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Buyer Products:
|
|
|
Vaccines |
|
|
Bacterial |
|
|
Combination |
|
|
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.
Buyer Products:
|
|
|
Mycological (Fungal) |
|
|
Antifungal Agents |
|
|
Narrow Spectrum |
|
|
Dermatology |
|
|
Tinea Barbae |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the bearded area by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Capitis |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the scalp by inhibiting biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Corporis (Ringworm) |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Cruris (Jock Itch) |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the groin and perineum by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Pedis |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the feet by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Unquium |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the nails by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Versicolor |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Nervous System |
|
|
Cryptococcal Meningitis |
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
Esophageal Candidiasis |
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Oropharyngeal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Urology |
|
|
Vaginal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
Viral |
|
|
DNA Viruses |
|
|
Herpesvirus |
|
|
Herpes Simplex Type 1 |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Herpes Simplex Type 2 |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Varicella Zoster |
|
|
Herpes Zoster (Shingles) |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Varicella (Chickenpox) |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Musculoskeletal System |
|
|
Skeletal Disorders |
|
|
Joint Disorders |
|
|
Osteoarthritis (OA) |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
Neurology |
|
|
Neurological Disorders |
|
|
Epilepsy |
|
|
Status Epilepticus |
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Buyer Products:
|
|
|
Headaches |
|
|
Vascular (Migraine) |
|
|
Prophylactic Treatments |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Buyer Products:
|
|
|
Neuromuscular Disorders |
|
|
Myasthenia Gravis (MG) |
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Buyer Products:
|
|
|
Parkinson`s Disease (PD) |
|
|
Adjunctive Treatments |
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by relaxing motor muscles and relieving pain.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Psychiatric Disorders |
|
|
Anxiety |
|
|
Generalized Anxiety Disorder (GAD) |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Sleep Disorders |
|
|
Insomnia |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Oncology |
|
|
Hematology |
|
|
Leukemia (White Blood Cell Cancer) |
|
|
Lymphoid |
|
|
Chronic |
|
|
Lymphocytic (CLL) |
|
|
Immunoglobulins
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by providing a therapeutic protein.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
Pain Management |
|
|
Anesthesia |
|
|
General (Systemic) |
|
|
Adjunctive |
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Buyer Products:
|
|
|
Ether-Based Agents
Therapeutics that result in anesthesia due to interfering with the physiological functioning of nerve cell membranes in the brain.
Buyer Products:
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Buyer Products:
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Reversal |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Buyer Products:
|
|
|
Narcotics |
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Non-Narcotics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Respiratory System |
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
Bronchitis |
|
|
Complications |
|
|
Bacterial Infections |
|
|
Antibacterial Agents (Antibiotics) |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
Emphysema |
|
|
Congenital |
|
|
Proteinase Inhibitors
Therapeutics that treat emphysema by providing certain proteins. The body's lack of ability to manufacture these proteins results in the disease state.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Upper Respiratory Tract Disorders |
|
|
Coughs/Colds |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Buyer Products:
|
|
|
Antihistamines/Decongestants/Opioids
Therapeutics that treat coughs and colds by suppressing histamine-related inflammation, preventing congestion and altering both the perception and emotional response to pain.
Buyer Products:
|
|
|
Antihistamines/Opioids
Therapeutics that treat coughs and colds by suppressing histamine-related inflammation and altering both the perception and emotional response to pain.
Buyer Products:
|
|
|
Surgery |
|
|
General |
|
|
Complications |
|
|
Hemorrhage |
|
|
Fibrinolysis Inhibitors
Therapeutics that treat complications involving bleeding after surgical procedures by inhibiting the breakdown of fibrin in blood clots.
Buyer Products:
|
|
|
Toxicology |
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of toxicity in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Substance Abuse |
|
|
Withdrawal |
|
|
Alcohol |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
Narcotics |
|
|
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.
Buyer Products:
|
|
|
Urology |
|
|
Urological Disorders |
|
|
Bladder |
|
|
Cystitis |
|
|
Urotoxin Neutralizing Agents
Therapeutics that inhibit cystis induced by toxic therapeutics by neutralizing these therapeutics.
Buyer Products:
|
|
|
Healthcare Services |
|
|
Patient Care |
|
|
Ambulatory/Outpatient |
|
|
Specialized |
|
|
Dialysis
The process of cleansing the blood of end stage renal disease patients (ESRD) through the use of a semipermeable membrane, which allows waste products to pass but retains most of the blood's normal constituents. Dialysis services can be provided in outpatient settings, in patients' home, or in hospitals as a contractor.
Buyer Products:
|
|
|
Medical Devices |
|
|
Anesthesiology |
|
|
Diagnostic |
|
|
Monitoring |
|
|
Systems |
|
|
Consciousness Monitoring
Systems designed to monitor the effect of anesthesia on patients during surgery.
Buyer Products:
|
|
|
Surgical |
|
|
General Procedure |
|
|
Delivery Systems |
|
|
Gas |
|
|
Breathing Accessories
Ancillary devices used to aid the administering of inhaled anesthetics, such as breathing bags and breathing masks.
Buyer Products:
|
|
|
Breathing Circuits
Devices which assist in physical mechanism of breathing.
Buyer Products:
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
Fluid Administration Sets
Intravenous fluid administration sets used to deliver anesthesia.
Buyer Products:
|
|
|
Pumps/Systems
Devices used to pump intravenous fluids at a consistent programmed rate.
Buyer Products:
|
|
|
Viscoelastics
Materials that can be applied to the skin and decrease resistance of to injected drugs.
Buyer Products:
|
|
|
Procedure/Region Specific |
|
|
Delivery Systems |
|
|
Epidural
Devices used to inject anesthetic into the epidural space to numb the legs and abdomen, which include catheters, needles, syrninges and other prepackaged kits.
Buyer Products:
|
|
|
Nerve Block
Devices used to assist in the delivery of nerve block anesthetic, which include catheters, needles and other prepackaged kits.
Buyer Products:
|
|
|
Spinal
Devices used to inject anesthetic into the spine, which include catheters, needles and other prepackaged kits.
Buyer Products:
|
|
|
Cardiology |
|
|
Surgical |
|
|
General Procedure |
|
|
Accessories |
|
|
Vessel Closure
Devices used to close heart blood vessels.
Buyer Products:
|
|
|
Procedure/Region Specific |
|
|
Revascularization |
|
|
Percutaneous Transluminal Coronary Angioplasty (PTCA) |
|
|
Restenosis Prevention |
|
|
Stents Systems |
|
|
Coated (Drug-Eluting Stents)
Stent systems coated with pharmaceuticals that aid the stent in preventing restenosis.
Target Products:
|
|
|
Clinical Diagnostics |
|
|
Histology |
|
|
Reagents |
|
|
Biomolecular Stains
Vital reagents used in the staining of tissue in order to view microscopically for pathology.
Target Products:
|
|
|
Fixatives/Preservatives
Chemical substances designed to preserve tissues for histological analysis and or act as microscope slide fixatives.
Target Products:
|
|
|
Kits |
|
|
In-Situ Hybridization (ISH)
Staining kits which utilize In-Situ hybridization techniques to mark specific cells for staining.
Target Products:
|
|
|
Immunoassays |
|
|
Reagents |
|
|
Calibrators |
|
|
Immunoassay
Reagents with known values (standards) designed to adjust parameters on immunoassay instrumentation so as to maximize accuracy of the analysis.
Target Products:
|
|
|
Drug Delivery |
|
|
Infusion Therapy |
|
|
Accessories |
|
|
Admixture Systems
Medical systems designed to combine multiple medications for delivery to the patients
Buyer Products:
|
|
|
Closed Blood Sampling Systems
Sampling systems which do not use needles to access infusion systems to obtain a blood sample.
Buyer Products:
|
|
|
Filtration Products
Device used to filter fluids for infusion.
Buyer Products:
|
|
|
Fluid Administration/Extension Sets
Filtered IV sets designed for infusion therapy.
Buyer Products:
|
|
|
Fluid Warmers
Medical devices used to maintain the warmth of the medical products prior to and during the infusion process.
Buyer Products:
|
|
|
Needleless Fluid Administration/Extension Sets
Valve systems designed to work without needles to prevent patient injuries.
Buyer Products:
|
|
|
Pump Sets
Pump sets designed specifically for infusion therapy.
Buyer Products:
|
|
|
Delivery Systems |
|
|
Elastomeric Infusors
Infusion delivery system designed for small-volume fluid transmission (home use).
Buyer Products:
|
|
|
Pumps |
|
|
Multiple Channel
Multiple channel pump designed to deliver more than one infusion therapy to patients.
Buyer Products:
|
|
|
Single Channel
Single channel pump designed to deliver only one infusion therapy to patients.
Buyer Products:
|
|
|
Syringe
Syringe used in place of a pump to deliver infusion therapy.
Buyer Products:
|
|
|
Integrated/Comprehensive Systems
Complete infusion systems that include pumps, monitoring devices and other accessories.
Buyer Products:
|
|
|
Vascular Access |
|
|
Peripheral Intravenous Catheters |
|
|
Infusion Sets
Complete infusion sets containing peripheral intravenous catheters.
Buyer Products:
|
|
|
Standard
Non-ported peripheral intravenous catheters.
Buyer Products:
|
|
|
Gastroenterology |
|
|
Treatment |
|
|
Stomach |
|
|
Tubes |
|
|
Feeding
A tube that carries food to the stomach.
Buyer Products:
|
|
|
General Surgery |
|
|
Invasive |
|
|
Surgical-Site Treatments |
|
|
Anti-Adhesives/Anti-Scarring |
|
|
Gels
Gel-based products applied during interventional procedures to prevent adhesion to medical devices or to prevent scarring of the surgical site
Buyer Products:
|
|
|
Sealants |
|
|
Hemostatic |
|
|
Delivery Systems
Medical devices designed to deliver hemostatic sealants to the surgical site
Buyer Products:
|
|
|
Sponges
Microfibrillar sponge used when conventional hemostasis procedures are not effective.
Buyer Products:
|
|
|
Topical
Topical mixture used when conventional hemostasis procedures are not effective.
Buyer Products:
|
|
|
Medical Supplies |
|
|
Diagnostic |
|
|
Clinical Examination |
|
|
Basic Examining Tools
Medical instruments used to examine and monitor basic physiological functions, such as reflex, blood pressure, heart rate, and pulmonary capacity. These instruments include stethoscopes, sphygmomanometers, percussion hammers and other similar items.
Buyer Products:
|
|
|
Safety and Sterilization |
|
|
Safety |
|
|
Waste Management
Products used to control and contain biohazardous materials, such as chemical waste, fluid waste, and solid waste. These products may include bags, containers, and other more advanced waste treatment systems.
Buyer Products:
|
|
|
Surgical |
|
|
Surgical Preparatory Accessories
Ancillary products designed to clean, prepare and organize surgical instruments and procedures, such as brushes, wipes, cleaners, instrument holders, guards/covers, drapes and other similar items.
Target Products:
|
|
|
Neurology |
|
|
Diagnostic |
|
|
Monitoring |
|
|
Monitors |
|
|
Electroencephalograph (EEG) |
|
|
Intraoperative
An electroencephalograph that is used during surgery.
Buyer Products:
|
|
|
Surgical |
|
|
General Procedure |
|
|
Surgical Sealants
A glue like material, made up of biomaterials, that is used to close up surgical incisions.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Surgical |
|
|
Procedure/Region Specific |
|
|
Cataract |
|
|
Viscoelastics
Material that can be applied to decrease resistance between two parts of the eye and promote healing and repair of damaged eye tissue.
Buyer Products:
|
|
|
Orthopedics |
|
|
Surgical |
|
|
Procedure Specific |
|
|
Bone Loss Reconstruction |
|
|
General |
|
|
Bone Fillers
Devices used to fill the formed bone cavity with hardening material.
Buyer Products:
|
|
|
Respiratory |
|
|
Treatment |
|
|
Assisted Breathing |
|
|
Intubation |
|
|
Breathing Circuits
Instrument used to measure respiratory parameters such as pressure.
Buyer Products:
|
|
|
Transfusion Medicine |
|
|
Blood Collection |
|
|
Accessories |
|
|
Collection/Storage
Devices, usually polymer plastic bags used for collection and subsequent storage of blood and blood components. Specific additives may or may not be incorporated to prevent the collected blood from clotting.
Buyer Products:
|
|
|
Apheresis Systems |
|
|
Plasma
Systems which separate and collect the plasma component of human blood while returning other blood components to the donor.
Buyer Products:
|
|
|
Platelets
Systems which separate and collect the platelet cell component of human blood while returning other blood components to the donor.
Buyer Products:
|
|
|
Red Blood Cells
Systems which separate and collect the red cell component of human blood while returning other blood components to the donor.
Buyer Products:
|
|
|
Blood Washers
Instruments used to wash blood cells in preparation for usage; they are often used to prepare frozen red blood cells for transfusion.
Buyer Products:
|
|
|
Filtration Systems
Medical devices used to filter leukocytes from blood during the transfusion process.
Buyer Products:
|
|
|
Viral Inactivation |
|
|
Plasma
Medical devices and technology which destroy infectious agents such as viruses in donor plasma without damaging the integrity of the plasma proteins.
Buyer Products:
|
|
|
Platelets
Medical devices and technology which destroy infectious agents such as viruses in blood products (platelets) without damaging the integrity of the donor platelet cells.
Buyer Products:
|
|
|
Red Blood Cells
Medical devices and technology which destroy infectious agents such as viruses in donor blood without damaging the integrity of the donor red blood cells.
Buyer Products:
|
|
|
Urology |
|
|
Surgical |
|
|
General Procedure |
|
|
Minimally Invasive/Cystoscopy |
|
|
Irrigation Pumps/Systems
Surgical instruments that pump fluids to irrigate/moisten the surface of the urinary organs
Buyer Products:
|
|
|
Treatment |
|
|
Renal |
|
|
Hemodialysis |
|
|
Components |
|
|
Concentrates
Chemicals used in hemodialysis.
Buyer Products:
|
|
|
Dialysate Parameter Monitors
Medical products used to monitor parameters such as fluid pressure, concentration, pH etc. during dialysis procedures.
Buyer Products:
|
|
|
Filtration |
|
|
Dialyzers
The instrument or medium used to effect chemical dialysis which allows for the diffusion of waste products and excess water into a dialysate solution.
Buyer Products:
|
|
|
Hemofilters
Filters used to separate the blood from the waste components during dialysis
through a convection process by creating negative pressure to draw out solute particles without using a dialysate solution.
Buyer Products:
|
|
|
Systems
A complete set of devices that act as a kidney to remove waste from the circulatory system.
Buyer Products:
|
|
|
Peritoneal Dialysis |
|
|
Components |
|
|
Solutions
Chemical agents used in peritoneal dialysis.
Buyer Products:
|
|
|
Systems |
|
|
Automated Peritoneal Dialysis (APD)
Complete set of instruments and devices that cycle solution to and from the patient's peritoneum during sleep.
Buyer Products:
|
|
|
Continuous Ambulatory (CAPD)
Complete set of instruments and devices that perform peritoneal dialysis that can be moved around with the patient.
Buyer Products:
|
|
|
Vascular |
|
|
Surgical |
|
|
General Procedure |
|
|
Accessories |
|
|
Vessel Closure
Devices used to close and repair vascular structures, including both complete systems and associated clamps, felts and pledgets.
Buyer Products:
|
|
|
Nutritional Health |
|
|
Dietary/Naturopathic Supplements |
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
Outsourced Services |
|
|
Development/Manufacturing Services |
|
|
Contract Manufacturing Organizations (CMO) |
|
|
Medical Devices
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.
Target Products:
|
|
|
Pharmaceuticals |
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Buyer Products:
|
|
|
Drug Delivery Technology |
|
|
Oral Delivery |
|
|
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.
Target Products:
|
|
|
Parenteral/Injectable Delivery |
|
|
Carrier Protein/Vector Based
Drug Delivery Technology used to deliver drugs using a carrier or vector protein.
Target Products:
|
|
|
Polymer Based
Drug Delivery Technology used to deliver drugs using a polymer based matrix to hold/enclose the drug.
Target Products:
|
|
|
Scientific Products |
|
|
Consumables |
|
|
Bioanalytical Chemistry |
|
|
Cell Biology |
|
|
Signal Transduction |
|
|
Reagents
Chemicals used in the preparation and analysis of samples during signal transduction analyses.
Target Products:
|
|
|
Immunology |
|
|
Kits |
|
|
Enzyme-Linked Immunoabsorbent Assay (ELISA)
Kits used for the generalized analysis of serum samples for the detection of antibodies to infectious diseases.
Target Products:
|
|
|
Reagents |
|
|
Proteins |
|
|
Antibodies
Immunology proteins that are used for the detection of specific substances, including conjugated, unconjugated, monoclonal and polyclonal antibodies.
Target Products:
|
|
|
Molecular Biology |
|
|
Electrochemiluminescence (ECL) |
|
|
Reagents
Chemicals used in the preparation and analysis of samples.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Angiotech Pharmaceuticals, Inc. (USA)
|
|
n/a | 530.487 | n/a | 30.05 | 1.62 | 1.69 | n/a | |
| Buyer | |||||||||
Bayer AG (ADR)
|
|
n/a | 60,168.995 | 10.66 | 16.43 | 1.40 | 1.39 | n/a | |
Cardinal Health, Inc.
|
|
n/a | 23,001.829 | 11.91 | 15.75 | 0.26 | 0.25 | 15.17 | |
Fresenius Medical Care AG & Co. (ADR)
|
|
n/a | 15,594.476 | 24.75 | 21.66 | 1.67 | 1.55 | n/a | |
Rexam PLC (ADR)
|
|
n/a | 7,164.067 | 15.13 | 17.52 | 1.05 | 0.97 | 12.33 | |
Hospira, Inc.
|
|
n/a | 6,408.154 | 61.23 | 18.82 | 2.13 | 1.86 | n/a | |
Pall Corporation
|
|
n/a | 4,683.240 | 22.29 | 20.91 | 2.13 | 2.11 | 4.62 | |
Abraxis BioScience, Inc.
|
|
n/a | 3,662.072 | n/a | 27.67 | 4.78 | 3.66 | n/a | |
Bausch & Lomb Inc.
|
|
n/a | 3,544.462 | 68.56 | 29.87 | 1.47 | 1.40 | 10.28 | |
| Target | |||||||||
Johnson & Johnson
|
|
n/a | 188,490.498 | 17.81 | 15.96 | 3.30 | 3.10 | 13.51 | |
Abbott Laboratories
|
|
n/a | 84,134.461 | 43.69 | 19.04 | 3.49 | 3.28 | 489.34 | |
Medtronic, Inc.
|
|
n/a | 64,157.340 | 22.29 | 21.04 | 5.12 | 4.78 | 11.90 | |
Boston Scientific Corp.
|
|
n/a | 20,481.354 | 34.83 | 36.05 | 2.48 | 2.42 | n/a | |
PerkinElmer, Inc.
|
|
n/a | 3,432.017 | 28.63 | 23.07 | 2.07 | 2.01 | n/a | |
Angiotech Pharmaceuticals, Inc. (USA)
|
|
n/a | 530.487 | n/a | 30.05 | 1.62 | 1.69 | n/a | |
Abaxis, Inc.
|
|
n/a | 445.738 | 41.39 | 33.67 | 5.02 | 4.58 | 4.84 | |
pSivida Limited (ADR)
|
|
n/a | 38.772 | n/a | n/a | 12.87 | n/a | n/a | |
Accelr8 Technology Corporation
|
|
n/a | 21.717 | n/a | n/a | 100.37 | n/a | 12.32 | |
Hydromer, Inc.
|
|
n/a | 7.940 | n/a | n/a | 0.98 | n/a | 3.71 | |
Biosensors International Pte Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Bridgehead International Ltd
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
MediVas, LLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Biocompatibles International plc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
W. L. Gore & Associates, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Specialty Coating Systems, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Halozyme Therapeutics, Inc.
|
|
55.00% | 697.773 | n/a | -38.42 | 302.54 | 172.39 | 9.86 | |
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 34,694.517 | 18.04 | 18.89 | 3.84 | 3.73 | 16.87 | |
WPP Group plc (ADR)
|
|
n/a | 15,922.859 | 17.90 | 15.44 | 1.32 | 1.33 | n/a | |
Computer Sciences Corporation
|
|
n/a | 9,663.491 | 24.85 | 13.69 | 0.65 | 0.61 | 5.26 | |
Acxiom Corporation
|
|
n/a | 1,788.499 | 43.19 | 24.55 | 1.28 | 1.26 | n/a | |
Ariba, Inc.
|
|
n/a | 806.081 | n/a | -163.50 | 2.70 | 2.56 | 99.71 | |
Angiotech Pharmaceuticals, Inc. (USA)
|
|
n/a | 530.487 | n/a | 30.05 | 1.62 | 1.69 | n/a | |
CapLease, Inc.
|
|
n/a | 480.214 | n/a | 10.00 | 3.31 | 2.72 | 1.19 | |
Cerus Corporation
|
|
n/a | 229.914 | n/a | -5.43 | 7.34 | 10.93 | 2.96 | |
Dyax Corp.
|
|
n/a | 226.444 | n/a | -2.82 | 18.94 | 18.40 | 66.96 | |
Trailer Bridge, Inc.
|
|
n/a | 141.933 | 13.85 | n/a | 1.22 | n/a | 203.93 | |
Micromet Inc.
|
|
n/a | 82.261 | n/a | -2.48 | 3.39 | 5.59 | 5.73 | |
HealthStream, Inc.
|
|
n/a | 60.668 | 29.99 | 27.20 | 1.68 | 1.59 | 95.54 | |
Attunity Ltd
|
|
n/a | 14.150 | n/a | n/a | 1.09 | n/a | n/a | |
MTM Technologies, Inc.
|
|
n/a | 13.509 | n/a | n/a | 0.05 | n/a | n/a | |
| Target | |||||||||
OctoPlus Pharmaceutical Development, B.V.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Medco Health Solutions Inc.
|
|
n/a | 23,950.252 | 26.48 | 24.57 | 0.55 | 0.53 | n/a | |
Amylin Pharmaceuticals, Inc.
|
|
n/a | 6,556.014 | n/a | -31.81 | 9.65 | 8.05 | 10.93 | |
DaVita Inc.
|
|
n/a | 6,512.177 | 17.57 | 18.62 | 1.28 | 1.21 | n/a | |
| Target | |||||||||
Abbott Laboratories
|
|
12.00% | 84,134.461 | 43.69 | 19.04 | 3.49 | 3.28 | 489.34 | |
General Electric Company
|
|
n/a | 422,654.902 | 19.78 | 18.66 | 2.54 | 2.48 | 17.27 | |
Johnson & Johnson
|
|
n/a | 188,490.498 | 17.81 | 15.96 | 3.30 | 3.10 | 13.51 | |
Merck & Co., Inc.
|
|
n/a | 112,400.892 | 23.44 | 16.63 | 4.82 | 4.62 | 6.53 | |
Medtronic, Inc.
|
|
n/a | 64,157.340 | 22.29 | 21.04 | 5.12 | 4.78 | 11.90 | |
Corning Incorporated
|
|
n/a | 37,840.671 | 19.92 | 17.41 | 7.04 | 6.37 | 4.82 | |
Boston Scientific Corp.
|
|
n/a | 20,481.354 | 34.83 | 36.05 | 2.48 | 2.42 | n/a | |
St. Jude Medical, Inc.
|
|
n/a | 15,382.574 | 27.93 | 25.61 | 4.37 | 4.17 | 60.00 | |
Bausch & Lomb Inc.
|
|
n/a | 3,544.462 | 68.56 | 29.87 | 1.47 | 1.40 | 10.28 | |
Edwards Lifesciences Corp
|
|
n/a | 2,792.278 | 23.95 | 23.38 | 2.66 | 2.61 | 7.71 | |
ev3 Inc.
|
|
n/a | 987.657 | n/a | -34.10 | 4.18 | 3.69 | 6.77 | |
Foxhollow Technologies, Inc.
|
|
n/a | 774.468 | 625.12 | 263.40 | 3.91 | 3.77 | 4.71 | |
The Spectranetics Corporation
|
|
n/a | 441.677 | 73.97 | 233.50 | 6.17 | 5.41 | 5.03 | |
XTENT, Inc.
|
|
n/a | 190.330 | n/a | -3.05 | n/a | 19.47 | 2.46 | |
SeraCare Life Sciences
|
|
n/a | 70.278 | 9.76 | n/a | 1.34 | n/a | 1.39 | |
X-Cell Medical, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
AbbeyMoor Medical, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Devax, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
ThermopeutiX, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Novocell, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Cook Group Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
CardioMind, Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 34,694.517 | 18.04 | 18.89 | 3.84 | 3.73 | 16.87 | |
Medco Health Solutions Inc.
|
|
n/a | 23,950.252 | 26.48 | 24.57 | 0.55 | 0.53 | n/a | |
| Target | |||||||||
General Electric Company
|
|
n/a | 422,654.902 | 19.78 | 18.66 | 2.54 | 2.48 | 17.27 | |
Johnson & Johnson
|
|
n/a | 188,490.498 | 17.81 | 15.96 | 3.30 | 3.10 | 13.51 | |
Merck & Co., Inc.
|
|
n/a | 112,400.892 | 23.44 | 16.63 | 4.82 | 4.62 | 6.53 | |
Abbott Laboratories
|
|
n/a | 84,134.461 | 43.69 | 19.04 | 3.49 | 3.28 | 489.34 | |
Medtronic, Inc.
|
|
n/a | 64,157.340 | 22.29 | 21.04 | 5.12 | 4.78 | 11.90 | |
Boston Scientific Corp.
|
|
n/a | 20,481.354 | 34.83 | 36.05 | 2.48 | 2.42 | n/a | |
St. Jude Medical, Inc.
|
|
n/a | 15,382.574 | 27.93 | 25.61 | 4.37 | 4.17 | 60.00 | |
Bausch & Lomb Inc.
|
|
n/a | 3,544.462 | 68.56 | 29.87 | 1.47 | 1.40 | 10.28 | |
Donaldson Company, Inc.
|
|
n/a | 3,283.431 | 21.78 | 20.77 | 1.71 | 1.58 | 5.26 | |
Edwards Lifesciences Corp
|
|
n/a | 2,792.278 | 23.95 | 23.38 | 2.66 | 2.61 | 7.71 | |
ev3 Inc.
|
|
n/a | 987.657 | n/a | -34.10 | 4.18 | 3.69 | 6.77 | |
Foxhollow Technologies, Inc.
|
|
n/a | 774.468 | 625.12 | 263.40 | 3.91 | 3.77 | 4.71 | |
The Spectranetics Corporation
|
|
n/a | 441.677 | 73.97 | 233.50 | 6.17 | 5.41 | 5.03 | |
XTENT, Inc.
|
|
n/a | 190.330 | n/a | -3.05 | n/a | 19.47 | 2.46 | |
SeraCare Life Sciences
|
|
n/a | 70.278 | 9.76 | n/a | 1.34 | n/a | 1.39 | |
Cook Group Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
CardioMind, Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
ThermopeutiX, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
OctoPlus Pharmaceutical Development, B.V.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
AbbeyMoor Medical, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
X-Cell Medical, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Novocell, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Devax, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 10,824.0 | 69.4 | 10,893.4 |
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 10,824.0 | 69.4 | 10,893.4 |
Cost of Revenue
|
5,636.0 | 4.4 | 5,640.4 |
SG&A Expense
|
2,378.0 | 9.6 | 2,387.6 |
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
Research & Development
|
666.0 | 22.6 | 688.6 |
Interest Expense
|
0.0 | 0.0 | 0.0 |
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
Unusual Expense (Income)
|
70.0 | 0.0 | 70.0 |
| Total Expenses | 8,750.0 | 36.6 | 8,786.6 |
Operating Income
|
2,074.0 | 32.9 | 2,106.9 |
| Non Operating Items | |||
Interest Expense (Inc.), Net Non-Oprtng
|
-10.0 | 5.0 | -5.0 |
Other, Net
|
-34.0 | -0.0 | -34.0 |
| Income Before Taxes | 2,030.0 | 37.9 | 2,067.9 |
| Income Taxes | 390.0 | 14.3 | 404.3 |
| Income After Taxes | 1,640.0 | 23.5 | 1,663.5 |
Net Income - Excl. Xord. Items
|
1,640.0 | 23.5 | 1,663.5 |
Net Income - Incl. Xord. Items
|
1,640.0 | 23.5 | 1,663.5 |
Income Avail. to Common
|
1,640.0 | 23.5 | 1,663.5 |
| Share Items | |||
Basic Avg. Shares Outstanding
|
650.0 | 17.8 | 667.8 |
Basic EPS - Excl. Xord. Items
|
2.52 | 1.32 | 2.49 |
Basic EPS - Incl. Xord. Items
|
2.52 | 1.32 | 2.49 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 661.0 | 18.0 | 679.0 |
F.D. EPS - Excl. Xord. Items
|
2.48 | 1.31 | 2.45 |
F.D. EPS - Incl. Xord. Items
|
2.48 | 1.31 | 2.45 |
| Dividends Per Common Share | 0.92 | 0.00 | 0.92 |
| Balance Sheet | |||
| Assets | |||
Cash and Equivalents
|
2,486.0 | 4.0 | 2,490.0 |
ST Investments
|
0.0 | 42.3 | 42.3 |
Accounts Receivable
|
1,993.0 | 30.9 | 2,023.9 |
Inventory
|
2,186.0 | 1.3 | 2,187.3 |
Prepayments and Advances
|
0.0 | 1.8 | 1.8 |
Other Current Assets
|
520.0 | 0.5 | 520.5 |
Current Assets
|
7,185.0 | 80.8 | 7,265.8 |
PPE
|
8,192.0 | 0.0 | 8,192.0 |
Accum D&A
|
-4,082.0 | 0.0 | -4,082.0 |
PPE, Net
|
4,110.0 | 11.4 | 4,121.4 |
| Goodwill & Intangibles | 2,078.0 | 0.0 | 2,078.0 |
| Long Term Investments | 0.0 | 47.8 | 47.8 |
| Other Assets | 0.0 | 0.0 | 0.0 |
Other LT Assets
|
1,286.0 | 24.9 | 1,310.9 |
| Total Assets | 14,659.0 | 164.9 | 14,823.9 |
| Liabilities | |||
| Accounts Payable | 0.0 | 1.0 | 1.0 |
| Payable/Accrued | 3,126.0 | 0.0 | 3,126.0 |
| Accrued Expenses | 0.0 | 1.5 | 1.5 |
ST Debt
|
190.0 | 0.0 | 190.0 |
Curr Port of LTD & Cap Lease Oblg
|
476.0 | 0.0 | 476.0 |
| Other (Current) Liabilities | 0.0 | 4.7 | 4.7 |
Current Liab.
|
3,792.0 | 7.1 | 3,799.1 |
LT Debt
|
2,051.0 | 0.0 | 2,051.0 |
Total LT Debt
|
2,051.0 | 0.0 | 2,051.0 |
Other LT Liab.
|
2,127.0 | 20.2 | 2,147.2 |
Total Liabilities
|
7,970.0 | 27.3 | 7,997.3 |
| Shareholders Equity | |||
| Common Stock | 683.0 | 0.9 | 683.9 |
| Additional Paid in Capital | 5,217.0 | 68.7 | 5,285.7 |
| Retained Earnings | 3,767.0 | 65.5 | 3,832.5 |
| Treasure Stock | -1,683.0 | 0.0 | -1,683.0 |
| Other Equity | -1,295.0 | 2.4 | -1,292.6 |
Total Equity
|
6,689.0 | 137.5 | 6,826.5 |
Total Liab. & Equity
|
14,659.0 | 164.9 | 14,823.9 |
Shares Outstanding
|
647.2 | 18.0 | 665.2 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 1,640.0 | 23.5 | 1,663.5 |
| CF Depreciation | 577.0 | 3.9 | 580.9 |
| CF Deferred Taxes | 8.0 | -1.5 | 6.5 |
| Other Non-Cash Items | 263.0 | 4.5 | 267.5 |
| Change in Working Capital | -192.0 | 1.4 | -190.6 |
| Total Cash From Operating Activities | 2,281.0 | 31.8 | 2,312.8 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -586.0 | -4.5 | -590.5 |
| Other Investing Cash Flows | 583.0 | 6.4 | 589.4 |
| Total Cash From Investing Activities | -3.0 | 1.9 | -1.1 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -490.0 | 0.0 | -490.0 |
| Purchase Or Sale of Stock | -806.0 | 3.3 | -802.7 |
| Purchase and Retirement of Debt | 224.0 | 0.0 | 224.0 |
| Other Financing Cash Flow | 272.0 | 0.1 | 272.1 |
| Total Cash From Financing Activities | -800.0 | -31.6 | -831.6 |
| Exchange Rate Effects | -53.0 | 0.0 | -53.0 |
| Net Change in Cash | 1,425.0 | 2.1 | 1,427.1 |
| Cash Taxes Paid | 296.0 | 16.6 | 312.6 |
| Cash Interest Paid | 108.0 | 0.0 | 108.0 |
Angiotech Pharmaceuticals, Inc. (USA)